Create Free Account

By creating account you will get access to hot stocks & personalised emails

Next Science Ltd

Healthcare AU NXS

0.14AUD
-0.01(6.67%)

Last update at 2024-11-13T05:10:00Z

Day Range

0.140.16
LowHigh

52 Week Range

0.120.50
LowHigh

Fundamentals

  • Previous Close 0.15
  • Market Cap45.28M
  • Volume401318
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.95220M
  • Revenue TTM23.31M
  • Revenue Per Share TTM0.09
  • Gross Profit TTM 9.15M
  • Diluted EPS TTM-0.08

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -12.68331M -9.34964M -11.91200M -14.35183M -13.74750M
Minority interest - - - - -
Net income -11.83417M -9.35718M -11.83649M -16.52667M -13.74750M
Selling general administrative 5.39M 3.91M 3.14M 8.45M 14.18M
Selling and marketing expenses 10.31M 7.37M 5.65M 0.65M -
Gross profit 9.15M 6.94M 2.92M 3.51M 2.47M
Reconciled depreciation 0.90M 0.79M 0.91M 0.81M -
Ebit -13.54834M -9.59997M -12.52074M -12.25068M -13.81451M
Ebitda -12.65124M -8.80969M -11.81915M -11.68544M -
Depreciation and amortization 0.90M 0.79M 0.70M 0.57M -
Non operating income net other - - - - -
Operating income -13.54834M -9.59997M -12.52074M -12.25068M -13.81452M
Other operating expenses 25.31M 18.56M 15.97M 16.60M 0.04M
Interest expense -0.01588M 1.04M 0.61M 2.10M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.01M 0.13M 0.14M 1.85M 0.07M
Net interest income -0.01588M 0.00004M 0.11M -2.65595M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.84914M 0.00754M -0.07551M 2.17M -
Total revenue 11.71M 8.95M 3.44M 4.06M 2.84M
Total operating expenses 22.74M 16.55M 15.45M 16.05M 16.66M
Cost of revenue 2.56M 2.01M 0.52M 0.55M 0.37M
Total other income expense net 0.87M 0.25M 0.61M -2.10114M 0.07M
Discontinued operations - - - - -
Net income from continuing ops -12.68331M -9.34964M -15.46612M -20.48505M -13.74750M
Net income applicable to common shares -12.68331M -9.34964M -11.91200M -14.35183M -13.74750M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 17.90M 12.46M 13.72M 23.64M 22.70M
Intangible assets 2.39M 2.41M 2.53M 2.33M 2.16M
Earning assets - - - - -
Other current assets - 0.54M 0.48M 0.45M 0.33M
Total liab 5.08M 4.42M 2.95M 4.73M 3.34M
Total stockholder equity 12.82M 8.04M 10.77M 18.91M 19.36M
Deferred long term liab - 1.37M 1.49M 1.37M 1.29M
Other current liab - 1.10M 0.77M 0.57M 0.52M
Common stock - 113.53M 102.92M 101.28M 90.69M
Capital stock 133.82M 113.53M 102.92M 101.28M 90.69M
Retained earnings -78.51123M -63.12851M -50.44520M -41.09556M -29.18356M
Other liab - 0.85M 1.30M 1.38M 1.33M
Good will - - - - -
Other assets - 0.04M 1.52M 1.41M 1.32M
Cash 9.24M 5.07M 7.00M 8.10M 16.91M
Cash and equivalents - - - - -
Total current liabilities 3.84M 2.61M 1.54M 3.23M 1.72M
Current deferred revenue - 0.27M 0.09M 1.91M 0.38M
Net debt - -3.85365M -6.72483M -7.81358M -16.42815M
Short term debt - 0.26M 0.17M 0.17M 0.20M
Short long term debt - - - - -
Short long term debt total - 1.22M 0.28M 0.29M 0.48M
Other stockholder equity - -1.90588M -41.70931M -41.27291M 0.00000M
Property plant equipment - 1.75M 0.92M 1.02M 1.21M
Total current assets 13.96M 8.26M 10.23M 20.25M 19.28M
Long term investments - - - - -
Net tangible assets - 6.99M 9.72M 17.95M 18.49M
Short term investments 0.04M 0.04M 0.37M 7.24M -
Net receivables 3.46M 1.74M 0.89M 3.39M 1.64M
Long term debt - - - - -
Inventory 0.72M 0.87M 1.50M 1.07M 0.40M
Accounts payable 1.41M 0.97M 0.52M 0.57M 0.63M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -42.36229M -41.70931M -41.27291M -42.14659M
Additional paid in capital - - - - -
Common stock total equity - - - 131.50M 129.45M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.04M 0.04M 0.04M 0.04M
Deferred long term asset charges - - - - -
Non current assets total 3.94M 4.20M 3.49M 3.39M 3.42M
Capital lease obligations 0.96M 1.22M 0.28M 0.37M 0.69M
Long term debt total - 0.96M 0.11M 0.12M 0.29M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.47572M -0.71676M -0.89172M -2.29521M -
Change to liabilities 0.53M -1.79967M 1.55M -0.21985M 1.50M
Total cashflows from investing activities -0.47572M -0.71676M -0.68680M -1.60802M -0.99277M
Net borrowings -0.25323M -0.21276M -0.22261M -0.13954M 7.74M
Total cash from financing activities 10.25M 1.43M 10.71M 23.68M 17.98M
Change to operating activities -0.38504M -0.05894M 0.00357M -0.73984M -0.09759M
Net income -11.83417M -9.34964M -11.30326M -16.45297M -13.74750M
Change in cash -2.25658M -7.97140M -1.57120M 9.70M 4.61M
Begin period cash flow 7.37M 15.34M 16.91M 7.21M -
End period cash flow 5.11M 7.37M 15.34M 16.91M 10.29M
Total cash from operating activities -10.93707M -8.26435M -11.90664M -12.33156M -12.25291M
Issuance of capital stock 10.89M 1.65M 11.32M 25.54M -
Depreciation 0.90M 0.79M 0.70M 0.57M 0.20M
Other cashflows from investing activities - - - - -
Dividends paid - - - -0.14160M -
Change to inventory 0.56M -0.38936M -0.62952M -0.22309M -0.22882M
Change to account receivables -0.80783M 2.50M -2.09705M -0.57835M -0.69254M
Sale purchase of stock -0.38563M -0.00623M -0.38774M -1.71800M 10.79M
Other cashflows from financing activities -0.25323M -0.21276M -0.22261M 0.07M -0.55669M
Change to netincome 0.10M 0.04M 0.47M 2.94M 0.77M
Capital expenditures 0.48M 0.72M 0.69M 1.61M 0.34M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - -17.77699M -14.85707M -15.59431M -15.38623M
Stock based compensation - - - - -
Other non cash items 10.94M 8.56M 11.00M 13.55M -
Free cash flow -11.41278M -8.98111M -12.59344M -13.93958M -

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NXS
Next Science Ltd		 -0.01 6.67% 0.14 - 128.21 1.94 4.08 1.12 -11.0461
AFP
AFT Pharmaceuticals Ltd		 -0.02 0.78% 2.55 17.71 19.08 1.35 3.31 1.56 10.94
VLS
Vita Life Sciences Ltd		 - -% 2.09 12.06 - 1.46 2.42 1.15 6.64
LV1
Live Verdure Ltd		 0.03 4.29% 0.73 - - 52.75 39.01 42.66 -5.083
PER
Percheron Therapeutics Limited		 -0.003 3.53% 0.08 - - 27.59 8.75 347.00 -4.4641

Reports Covered

Stock Research & News

View All

Profile

Next Science Limited engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial gel that conforms to the postoperative wound; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.

Next Science Ltd

Australia Square, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Ms. Judith Mitchell M.B.A. MD, CEO & Exec. Director NA
Dr. Matthew Franco Myntti Founder & CTO NA
Ms. Jacqueline Butler CA (ICAEW) Chief Financial Officer NA
Mr. Jon Swanson Chief Operating Officer NA
Mr. Michael Morello VP of Sales NA
Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD Company Sec. NA
Mr. Harry Thomas Hall MD, CEO & Director NA
Marc Zimmerman Chief Financial Officer NA
Mr. Robert Bell Senior Vice President of North American Sales NA
Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.